Since the first approval of EGFR-TKIs, second-generation TKIs such as afatinib (11) (targeting EGFR and ERBB2) and the third-generation TKI osimertinib (12) (targeting EGFR carrying the T790M resistance mutation) have been developed and approved for use in NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.